Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02610868 · ClinicalTrials.gov registry record · Phase 3
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
A Phase 3 study of Sialorrhea, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT02610868 is a Phase 3 study of Sialorrhea that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 187 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT02610868, a Phase 3 study of Sialorrhea, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
Conditions Studied
Interventions
- DRUG MYOBLOC
Study Locations (20)
Florida
- - Atlantis
- - Boca Raton
- - Orlando
- - Port Charlotte
Arizona
- - Phoenix
- - Scottsdale
- - Scottsdale
California
- - Loma Linda
- - Los Angeles
Kansas
- - Kansas City
- - Overland Park
Colorado
- - Aurora
Georgia
- - Atlanta
Maryland
- - Elkridge
Michigan
- - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02610868
The ClinicalTrials.gov registry entry for NCT02610868 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sialorrhea appearing as the primary indexed condition, and to 1 intervention - of which MYOBLOC is the first listed.
NCT02610868 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT02610868 about?
NCT02610868 is a clinical study titled "Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults". Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
What is the current status of trial NCT02610868?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2015-10. Estimated completion is 2017-06.
What conditions does trial NCT02610868 study?
This clinical trial studies the following conditions: Sialorrhea.
What interventions are being tested in trial NCT02610868?
The interventions under investigation include: MYOBLOC (DRUG).
Who is sponsoring clinical trial NCT02610868?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02610868 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sialorrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.